title: Anti-idiotype x anti-LFA-1 bispecific antibodies inhibit metastasis of B cell lymphoma.
abstract: Abs to adhesion molecules can block tumor metastasis. However, they may also block the function of normal cells. To circumvent this adverse effect, we proposed the use of bispecific Abs that bind simultaneously to an adhesion receptor and to a tumor-specific Ag. Such Abs bind more avidly to tumor cells that coexpress both target Ags than to normal cells. The Id of the surface Ig of malignant B lymphocytes is a tumor-specific Ag. We therefore produced a bispecific Ab with specificity to the adhesion molecule LFA-1 and to the Id of the murine B cell lymphoma 38C-13. Here we demonstrate that this Ab blocked liver metastasis in mice carrying primary s.c. tumors and partially inhibited lymph node metastasis. Migration of 38C-13 cells to liver and lymph nodes was inhibited by the bispecific Ab, while migration to spleen was not affected. Hence, the bispecific Ab-mediated reduction in liver and lymph node metastasis resulted at least in part from reduced homing to these organs. In contrast to anti-LFA-1 monospecific Abs, the anti-Id x anti-LFA-1 bispecific Ab did not affect immune responses such as delayed-type hypersensitivity. Hence, bispecific Abs against adhesion molecules and against tumor-specific Ags may selectively block tumor metastasis in a way that may leave much of the immune system intact.
authors.affiliation: Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Sharon
authors.initials: S
authors.lastname: Cohen
authors.forename: Joseph
authors.initials: J
authors.lastname: Haimovich
authors.forename: Nurit
authors.initials: N
authors.lastname: Hollander
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000494:pharmacology*; D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000494:pharmacology*; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002465:Cell Movement / Q000276:immunology; D005260:Female; D006131:Growth Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D006825:Hybridomas; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D008207:Lymphatic Metastasis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology*; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009928:Organ Specificity / Q000276:immunology; D051381:Rats; D014407:Tumor Cells, Cultured
chemical_list: D000888:Antibodies, Anti-Idiotypic; D018033:Antibodies, Bispecific; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D007075:Immunoglobulin M; D016169:Lymphocyte Function-Associated Antigen-1; C044203:anti-IgM